What is Critical Diagnostics?
Critical Diagnostics, operating at the intersection of medical technology and cardiovascular health, specializes in the development of novel biomarkers. These biomarkers are designed to empower physicians with enhanced tools for optimizing patient care within cardiovascular diseases, while simultaneously addressing the critical need to contain escalating healthcare costs. The company has established a robust global presence, evidenced by its distribution partnerships spanning 50 countries, effectively reaching two-thirds of the world's population.
How much funding has Critical Diagnostics raised?
Critical Diagnostics has raised a total of $11.1M across 2 funding rounds:
Private Equity
$2.6M
Private Equity
$8.5M
Private Equity (2012): $2.6M, investors not publicly disclosed
Private Equity (2018): $8.5M, investors not publicly disclosed
What's next for Critical Diagnostics?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Critical Diagnostics. This capital infusion is expected to accelerate the company's research and development initiatives, potentially expanding its biomarker portfolio and refining its existing diagnostic solutions. Furthermore, the financing will likely bolster its global commercialization efforts, strengthening its distribution networks and market penetration in key international regions. The focus on optimizing patient care and reducing healthcare expenditures positions Critical Diagnostics for significant impact and sustained expansion within the competitive medical diagnostics landscape.
See full Critical Diagnostics company page
